In fact, Rybelsus is not FDA-approved for weight loss, and when used off-label for this purpose, it delivers far more modest results
BENEFITS Triple receptor activation studied for simultaneous GLP-1, GIP, and glucagon engagement Metabolic research explored in Phase 2 clinical trials with notable body-composition results Glucagon component linked to thermogenesis and energy-expenditure pathways Next-generation compound investigated as an advancement over dual-agonist approaches Comparative pharmacology assessed alongside mono- and dual-agonists in research settings WHAT RESEARCHERS LOOK AT Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors Additive effects of glucagon-receptor activation on energy expenditure Dose-response and tolerability profiling from clinical-trial data Comparative outcomes vs tirzepatide and semaglutide Pharmacokinetic profiling and receptor selectivity
GSH and redox control The initiation of necroptosis is sensitive to cellular redox state
These drugs also improve blood sugar, blood pressure, and cholesterol, and reduce the risk of heart attacks and strokes
TouchREVIEWS in endocrinology , 2022, 18.1: 10
